Amoxicillin-loaded Nanotechnological Carriers for the Effective Treatment of Helicobacter pylori Infection

The bacterium Helicobacter pylori (H. pylori) is known to cause gastroduodenal disorders associated with the stomach lining that grows in the gastrointestinal tract, and can cause gastritis, peptic ulcer, gastric lymphoma, and stomach cancer. Nearly 50% of people worldwide suffer from H. pylori infection. This infection is more prominent in poor nations and undeveloped countries, and is caused by multiple factors, such as consumption of unhygienic food, crowded living style, etc. In the eradication treatment of gastric H. pylori infection, conventional dosage forms have various adverse effects on patients. In this study, we have explored current developments in the utilization of nanotechnological carriers for the successful management of H. pylori infection. In order to combat rising amoxicillin resistance, this review has focused on therapeutic strategies that use cyclodextrins, niosomes, liposomes, microspheres, nanoparticles, solid lipid nanoparticles, and nanostructure nanoparticles to improve therapy against H. pylori. The entrapment of amoxicillin in various nanotechnological carriers enhances its effectiveness and reduces adverse effects. These carriers lead to targeted drug release and improve drug penetration to the gastroduodenal disease site that locally controls and adjusts the drug release. For the effective treatment of H. pylori infection, nanotechnological carriers have provided a new avenue for the development of innovative, high-impact, and low-dose systems. The main objective of this review was to outline the present limitations of H. pylori therapy and new potential alternatives, as well as to report how nanotechnological carriers may be used to overcome treatment shortcomings.